A 5-year single center study assessing the longitudinal effects of Ivacaftor and medicine possession ratio in patients with Cystic Fibrosis carrying the Gly551Asp mutation
Latest Information Update: 18 Feb 2021
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 18 Feb 2021 New trial record
- 12 Feb 2021 Results published in the Thorax